New HIV shot formula tested for safety and absorption

NCT ID NCT04484337

Completed Knowledge-focused Sponsor: ViiV Healthcare Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a more concentrated version of the long-acting HIV drug cabotegravir in 138 healthy adults. Researchers gave the injection in different ways (into muscle or under the skin) to see how the body processes it and to check for side effects. The goal was to gather safety and drug-level information, not to treat HIV.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Show contact details

Locations

GSK Investigational Site

Orlando, Florida, 32806, United States
GSK Investigational Site

Las Vegas, Nevada, 89113, United States
GSK Investigational Site

Berlin, New Jersey, 08009, United States
GSK Investigational Site

Austin, Texas, 78744, United States
GSK Investigational Site

Auckland, 1010, New Zealand